Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.
2 reports, 1 independent
Updated Oct 8
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Leerink partners
U.S. investment bank
Related events
- Leerink Partners began coverage on Novogen Limited shares on October 20, 2026.
- Leerink Partners reduced its target price for Keros Therapeutics on November 2, 2026.
- Leerink Partners cut its shares rating for Akebia Therapeutics on November 3, 2026.
- Illumina and Leerink partners are involved in a new development.